IDEOGEN A.G. was founded in Basel by Tuygan Göker with the mission to incubate pharma investments and research & development.
TrPharm joint venture launched as IDEOGEN affiliate to target commercialisation, manufacturing and R&D of specialty therapies in MENA(T) Region.
IDEOGEN Invest into Novimmune and CEO Tuygan Göker becomes board member.
Konsina Biopharmaceuticals launched under joint venture with Emcure Group to commercialise injectable oncology, hematology and infectious disease therapies in Turkey and Eastern Europe.
IDEOGEN affiliate breaks ground on biologics manufacturing facility in Istanbul, Turkey as manufacturing hub for Middle East, North Africa and Turkey.
IDEOGEN affiliate successfully completes First-in-Human Phase 1 Clinical Study for a Novel-Anti-Interleukin 1 Biologic Agent.
IDEOGEN acquires remaining shares of Konsina from Emcure to further expand operations in Eastern Europe and MENA.
IDEOGEN opens Ideogen LABS in Spain and Netherlands to expand R&D and operational capabilities in the EU.
IDEOGEN A.G. initiates research program at ETH to identify multiple first-in-kind novel biomarkers for unmet medical needs related to brain diseases.
IDEOGEN opens subsidiary in Austria for the launch of specialty therapies.
IDEOGEN Group GmBH incorporated as headquarters for consolidation of international subsidiaries and affiliates in Switzerland.
IDEOGEN consolidates all companies under its Ideogen Group GmBH HQ in Switzerland.
Launch of BiCNU & Sidovis
Launch of the MAP taken over from Clinigen in Europe & Turkey
Konsina becomes IDEOGEN Turkey
COMPANY HISTORY
COMPANY HISTORY